| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;99:1951-1958.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab
One-Year Outcome in the EPILOG Trial
From the Departments of Cardiology or Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio (A.M.L., J.E.B., C.B., E.J.T.); the Department of Medicine, Duke Clinical Research Institute, Duke University, Durham, NC (J.E.T., R.M.C.); Christ Hospital, Cincinnati, Ohio (D.J.K.); Moses Cone Memorial Hospital, Greensboro, NC (T.A.K.); William Beaumont Hospital, Royal Oak, Mich (G.C.T.); Baylor College of Medicine and the Methodist Hospital, Houston, Tex (N.S.K.); and Centocor, Malvern, Pa (C.F.C., K.M.A., H.F.W.).
Correspondence to A. Michael Lincoff, MD, Department of Cardiology, Desk F25, The Cleveland Clinic Foundation, Cleveland, OH 44195.
Background—Blockade of the platelet glycoprotein IIb/IIIa receptor with the monoclonal antibody fragment abciximab was shown in a placebo-controlled randomized trial to reduce the incidence of acute ischemic complications within 30 days among a broad spectrum of patients undergoing percutaneous coronary revascularization. The durability of clinical benefit in this setting has not been established.
Methods and Results—A total of 2792 patients enrolled in the Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade (EPILOG) trial were followed with maintenance of double-blinding for 1 year. Patients had been assigned at the time of their index coronary interventional procedure to receive placebo with standard-dose, weight-adjusted heparin (100 U/kg initial bolus), abciximab with standard-dose, weight-adjusted heparin, or abciximab with low-dose, weight-adjusted heparin (70 U/kg initial bolus). The primary outcome was the composite of death, myocardial infarction, or urgent repeat revascularization by 30 days; this composite end point and its individual components were also assessed at 6 months and 1 year. Rates of any repeat revascularization (urgent or elective), target vessel revascularization, and a composite of death, myocardial infarction, or any repeat revascularization were also reported. Follow-up at 1 year was 99% complete for survival status and 97% complete for other end points. By 1 year, the incidence of the primary composite end point was 16.1% in the placebo group, 9.6% in the abciximab with low-dose heparin group (P<0.001), and 9.5% in the abciximab with standard-dose heparin group (P<0.001). Each of the components of this composite end point was reduced to a similar extent. Nonurgent or target vessel repeat revascularization rates were not significantly decreased by abciximab therapy. Mortality rates over 1 year increased with increasing levels of periprocedural creatine kinase MB fraction elevation.
Conclusions—Acute reductions in ischemic events after percutaneous coronary intervention by abciximab are sustained over follow-up to at least 1 year. Early periprocedural myocardial infarctions suppressed by this therapy are associated with long-term mortality rates.
Key Words: angioplasty • glycoproteins • receptors • revascularization • thrombosis • platelets
This article has been cited by other articles:
 |
|
 |
|
  G. Ndrepepa, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, M. Seyfarth, J. Pache, J. Dirschinger, et al. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial Eur. Heart J., February 2, 2008; 29(4): 455 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Miller, K. N. Garratt, M. F. Burritt, R. J. Lennon, G. S. Reeder, and A. S. Jaffe Baseline troponin level: key to understanding the importance of post-PCI troponin elevations Eur. Heart J., May 1, 2006; 27(9): 1061 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Lansky, J. S. Hochman, P. A. Ward, G. S. Mintz, R. Fabunmi, P. B. Berger, G. New, C. L. Grines, C. G. Pietras, M. J. Kern, et al. Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare Professionals From the American Heart Association Circulation, February 22, 2005; 111(7): 940 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lincoff, N. S. Kleiman, D. J. Kereiakes, F. Feit, J. A. Bittl, J. D. Jackman, I. J. Sarembock, D. J. Cohen, D. Spriggs, R. Ebrahimi, et al. Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization: REPLACE-2 Randomized Trial JAMA, August 11, 2004; 292(6): 696 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Miller, K. N. Garratt, M. F. Burritt, G. S. Reeder, and A. S. Jaffe Timing of Peak Troponin T and Creatine Kinase-MB Elevations After Percutaneous Coronary Intervention Chest, January 1, 2004; 125(1): 275 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bakhai, G. W. Stone, C. L. Grines, S. A. Murphy, L. Githiora, R. H. Berezin, D. A. Cox, T. Stuckey, J. J. Griffin, J. E. Tcheng, et al. Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial Circulation, December 9, 2003; 108(23): 2857 - 2863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. O. Williams A twist in our understanding of enzyme elevation after coronary intervention J. Am. Coll. Cardiol., December 3, 2003; 42(11): 1906 - 1908. [Full Text] [PDF]
|
|
|
|
|
|
J. P. A. Ioannidis, E. Karvouni, and D. G. Katritsis Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1406 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P Dobesh, S. L Lanfear, J. R Abu-Shanab, J. E Lakamp, S. Gowda, and M. Y Haikal Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI Ann. Pharmacother., October 1, 2003; 37(10): 1375 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Mehta and G. M. Chertow Acute Renal Failure Definitions and Classification: Time for Change? J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2178 - 2187. [Full Text] [PDF]
|
|
|
|
|
|
M. A Crouch, J. M Nappi, and K. I Cheang Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome Ann. Pharmacother., June 1, 2003; 37(6): 860 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gorchakova, W. Koch, N. von Beckerath, J. Mehilli, A. Schomig, and A. Kastrati Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement Eur. Heart J., May 1, 2003; 24(9): 820 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Brener, S. G. Ellis, J. Schneider, C. Apperson-Hansen, and E. J. Topol Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry Eur. Heart J., April 1, 2003; 24(7): 630 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, J. A. Bittl, R. A. Harrington, F. Feit, N. S. Kleiman, J. D. Jackman, I. J. Sarembock, D. J. Cohen, D. Spriggs, R. Ebrahimi, et al. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial JAMA, February 19, 2003; 289(7): 853 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Lenderink, E Boersma, C Heeschen, A Vahanian, M.-J de Boer, V Umans, M.J.B.M van den Brand, C.W Hamm, M.L Simoons, and for the CAPTURE investigators Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA Eur. Heart J., January 1, 2003; 24(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Karvouni, D. G. Katritsis, and J. P. A. Ioannidis Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J. Am. Coll. Cardiol., January 1, 2003; 41(1): 26 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Brener, B. W. Lytle, J. P. Schneider, S. G. Ellis, and E. J. Topol Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1961 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M G Gunning, I L Williams, D E Jewitt, A M Shah, R J Wainwright, and M R Thomas Coronary artery perforation during percutaneous intervention: incidence and outcome Heart, December 1, 2002; 88(5): 495 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.J. Brener, S.G. Ellis, J. Schneider, and E.J. Topol Frequency and long-term impact of myonecrosis after coronary stenting Eur. Heart J., June 1, 2002; 23(11): 869 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Drewe and R J Powell Clinically useful monoclonal antibodies in treatment J. Clin. Pathol., February 1, 2002; 55(2): 81 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Buller and R. G. Carere New advances in the management of acute coronary syndromes: 3. The role of catheter-based procedures Can. Med. Assoc. J., January 1, 2002; 166(1): 51 - 61. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Kapadia, C. T. Bajzer, K. M. Ziada, D. L. Bhatt, O. M. Wazni, M. J. Silver, E. G. Beven, K. Ouriel, and J. S. Yadav Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting: A Safe and Effective Adjunctive Therapy Stroke, October 1, 2001; 32(10): 2328 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. McCune, J. P. Gockerman, and D. A. Rizzieri Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma JAMA, September 12, 2001; 286(10): 1149 - 1152. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bogousslavsky and J. R. Leclerc Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke Neurology, September 1, 2001; 57(90002): S53 - 57. [Abstract] [Full Text]
|
|
|
|
|
|
G. W. Stone, R. Mehran, G. Dangas, A. J. Lansky, R. Kornowski, and M. B. Leon Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention: A Device-Specific Analysis of 7147 Patients Circulation, August 7, 2001; 104(6): 642 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Zvara Treatment of Perioperative Myocardial Ischemia Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 2001; 5(2): 166 - 183. [Abstract] [PDF]
|
|
|
|
|
|
K. M. Anderson, R. M. Califf, G. W. Stone, F.-J. Neumann, G. Montalescot, D. P. Miller, J. J. Ferguson III, J. T. Willerson, H. F. Weisman, and E. J. Topol Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2059 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. I. Lev, J. I. Osende, M. F. Richard, J. A. Robbins, J. A. Delfin, O. Rodriguez, S. K. Sharma, T. Jayasundera, J. J. Badimon, and J. D. Marmur Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function J. Am. Coll. Cardiol., March 1, 2001; 37(3): 847 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, D. B. Mark, J. E. Tcheng, R. M. Califf, M. V. Bala, K. M. Anderson, L. Davidson-Ray, J. D. Knight, C. F. Cabot, and E. J. Topol Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization : Results From the EPILOG Randomized Trial Circulation, December 12, 2000; 102(24): 2923 - 2929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA, September 27, 2000; 284(12): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.M. Lincoff and E.J. Topol Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? Eur. Heart J., June 1, 2000; 21(11): 863 - 867. [PDF]
|
|
|
|
|
|
C. Heeschen, C. W. Hamm, J. Bruemmer, M. L. Simoons, and for the CAPTURE Investigators Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1535 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, R. M. Califf, and E. J. Topol Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1103 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Topol and J. S. Yadav Recognition of the Importance of Embolization in Atherosclerotic Vascular Disease Circulation, February 8, 2000; 101(5): 570 - 580. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yeghiazarians, J. B. Braunstein, A. Askari, and P. H. Stone Unstable Angina Pectoris N. Engl. J. Med., January 13, 2000; 342(2): 101 - 114. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, R. M. Califf, D. J. Moliterno, S. G. Ellis, J. Ducas, J. H. Kramer, N. S. Kleiman, E. A. Cohen, J. E. Booth, S. K. Sapp, et al. Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors N. Engl. J. Med., July 29, 1999; 341(5): 319 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Sustained Benefit of Abciximab at One Year Journal Watch Cardiology, June 3, 1999; 1999(603): 1 - 1. [Full Text]
|
|